Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTYVX59)

• DTT Name: Protein kinase C (PRKC)
• Gene Name: PRKC
• DTT Type: Clinical trial target; [1]
• BioChemical Class: Kinase
• UniProt ID: NOUNIPROTAC
• TTD ID: T88318

Molecular Interaction Atlas (MIA) of This DTT

10 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Synthetic hypericin	DMXU4ON	Virus infection	1A24-1D9Z	Phase 3	[1]
AEB07	DMJVN89	Transplant rejection	NE84	Phase 2	[2]
APH-0812	DM756GE	Human immunodeficiency virus-1 infection	1C62	Phase 2	[3]
Bryostatin-1	DM1JOXY	Alzheimer disease	8A20	Phase 2	[4]
CYCLOPLATAM	DMXR8WN	Solid tumour/cancer	2A00-2F9Z	Phase 2	[5]
HO/03/03	DMA6HQJ	Diabetic foot ulcer	BD54	Phase 2	[6]
LXS196	DM65MEL	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[7]
AEB701	DM8I4G0	Melanoma	2C30	Phase 1	[8]
GCC-1290K	DMJ7WRI	Parkinson disease	8A00.0	Phase 1	[9]
SAFINGOL	DMBGUDR	Psoriasis vulgaris	EA90	Phase 1	[10]

3 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tecadenoson	DM9T6MS	Atrial fibrillation	BC81.3	Discontinued in Phase 3	[11]
Calphostin C	DM9X2D0	N. A.	N. A.	Terminated	[13]
Ro-31-8830	DMTIW6K	Inflammation	1A00-CA43.1	Terminated	[14]

1 Preclinical Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rottlerin	DMOQ63E	Parkinson disease	8A00.0	Preclinical	[12]

3 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[15]
G6976	DMEZO4M	Solid tumour/cancer	2A00-2F9Z	Investigative	[16]
Staurosporine	DM0E9BR	Discovery agent	N.A.	Investigative	[13]

References

• [1] Characterization of the interaction of hypericin with protein kinase C in U-87 MG human glioma cells. Photochem Photobiol. 2006 May-Jun;82(3):720-8.
• [2] What's next in the pipeline. Am J Transplant. 2008 Oct;8(10):1972-81.
• [3] Targeting the protein kinase C family: are we there yet. Nat Rev Cancer. 2007 Jul;7(7):554-62.
• [4] Bryostatin-1: a promising compound for neurological disorders. Front Pharmacol. 2023 Jun 7;14:1187411.
• [5] Effect of anti-tumor agents cisplatin and cycloplatam on membrane protein kinase C activity in murine T-lymphocytes. Biokhimiia. 1996 Oct;61(10):1866-73.
• [6] WO patent application no. 2014,0853,81, Pharmaceutical combinations.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Changes in Serum Cytokine Profile after AEB071 (Sotrastaurin) or Tacrolimus versus Their Combinations in Rat Heterotopic Cardiac Allografts. J Korean Soc Transplant. 2012 Dec;26(4):248-253.
• [9] Inhibitory effect of glutamate release from rat cerebrocortical synaptosomes by dextromethorphan and its metabolite 3-hydroxymorphinan. Neurochem Int. 2009 Jul;54(8):526-34.
• [10] The role of protein kinase C in the synergistic interaction of safingol and irinotecan in colon cancer cells. Int J Oncol. 2009 Dec;35(6):1463-71.
• [11] Protein kinase C as a molecular target for cancer prevention by selenocompounds. Nutr Cancer. 2001;40(1):55-63.
• [12] Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42.
• [13] Protein kinase C zeta isoform is critical for proliferation in human glioblastoma cell lines. J Neurooncol. 2000 Apr;47(2):109-15.
• [14] Oral, anti-inflammatory activity of a potent, selective, protein kinase C inhibitor. Agents Actions. 1992 Sep;37(1-2):85-9.
• [15] Protein kinase epsilon dampens the secretory response of model intestinal epithelia during ischemia. Surgery. 2001 Aug;130(2):310-8.
• [16] The protein kinase C inhibitor G 6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints. Cancer Res. 2003 Jan 1;63(1):31-5.